Summary & Overview
CPT 88341: Additional Single Antibody Stain Procedure in Pathology
CPT code 88341 represents each additional single antibody stain procedure performed on a specimen during immunohistochemistry or immunocytochemistry testing. This code is critical in pathology and laboratory medicine, supporting the detailed analysis of tissue samples for diagnostic and prognostic purposes. The procedure is typically performed in laboratory settings and is essential for identifying specific cellular markers, which play a pivotal role in the diagnosis and management of conditions such as cancer.
Major national payers, including Aetna, Blue Cross Blue Shield, Cigna Health, Medicare, and UnitedHealthcare, provide coverage for this service, reflecting its widespread clinical importance. Readers will gain insight into the clinical context of 88341, its relationship to primary and related pathology codes, and the policy landscape surrounding its use. The publication covers benchmarks, policy updates, and relevant modifiers, offering a comprehensive overview for stakeholders in laboratory medicine and pathology billing. Understanding the nuances of 88341 is vital for accurate reporting and reimbursement, as well as for maintaining compliance with payer requirements and clinical best practices.
CPT Code Overview
CPT code 88341 is used to report each additional single antibody stain procedure performed on a specimen as part of immunohistochemistry or immunocytochemistry testing. This code is listed separately in addition to the primary procedure and is commonly utilized in pathology and laboratory settings to provide detailed analysis of tissue samples. The typical site of service for this procedure is a laboratory, specifically Place of Service 81. Immunohistochemistry and immunocytochemistry are essential techniques in modern pathology, enabling precise identification of cellular markers and aiding in the diagnosis and classification of various diseases, including cancers.
Clinical & Coding Specifications
Clinical Context
A patient presents with a suspicious lesion, such as a mass in the breast, lung, prostate, colon, or bone/soft tissue. A biopsy specimen is obtained and sent to the laboratory for evaluation. The pathologist performs immunohistochemistry or immunocytochemistry to identify specific antigens within the tissue, aiding in diagnosis and classification of the neoplasm. The primary antibody stain is performed first (coded with 88342), and additional single antibody stains are performed as needed to further characterize the tumor, each billed with 88341. This process is essential for determining tumor origin, subtype, and guiding treatment decisions.
Coding Specifications
-
Modifier
26: Used to indicate the professional component, when only the pathologist's interpretation and report are provided (not the technical laboratory work). -
Modifier
59: Used to indicate a distinct procedural service, when multiple stains are performed that are separate and not overlapping.
| Provider Taxonomy Code | Specialty Name |
|---|---|
207ZP0102X | Anatomic Pathology |
207ZP0105X | Cytopathology |
207ZP0104X | Clinical Pathology/Laboratory Medicine |
These taxonomies represent providers specializing in pathology and laboratory medicine, including anatomic and cytopathology.
Related Diagnoses
-
C50.911: Malignant neoplasm of unspecified site of right female breast- Relevant for breast biopsies where immunohistochemistry helps determine tumor subtype and receptor status.
-
C34.90: Malignant neoplasm of unspecified part of unspecified bronchus or lung- Used for lung biopsies; immunohistochemistry assists in differentiating tumor types and guiding therapy.
-
D49.2: Neoplasm of unspecified behavior of bone, soft tissue, and skin- Applied to cases where the behavior of the neoplasm is unclear; immunohistochemistry aids in classification.
-
C61: Malignant neoplasm of prostate- For prostate biopsies, immunohistochemistry is used to confirm malignancy and identify tumor characteristics.
-
C18.9: Malignant neoplasm of colon, unspecified- Used for colon biopsies; immunohistochemistry helps in diagnosis and determining the origin of the tumor.
Related CPT Codes
-
88342: Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain procedure. Used for the first antibody stain on a specimen;88341is used for each additional single antibody stain. -
88305: Level IV - Surgical pathology, gross and microscopic examination. Often used for the initial evaluation of biopsy specimens before immunohistochemical stains are ordered. -
88312: Special stain including interpretation and report; Group I for microorganisms. Used when special stains for microorganisms are required, which may be performed alongside immunohistochemistry. -
88313: Special stain including interpretation and report; Group II, all other. Used for other special stains not specific to microorganisms, sometimes in conjunction with immunohistochemistry.
88341 is commonly used together with 88342 for comprehensive immunohistochemical analysis. 88305 is typically performed prior to immunohistochemistry to assess the specimen. 88312 and 88313 may be used as alternatives or adjuncts depending on the diagnostic needs.
National Reimbursement Benchmarks
Nationally, the mean rate for CPT code 88341 is highest with Aetna at $94.70, while the average commercial rate (BUCA) stands at $71.07. Medicare's mean rate is $65.53, which is lower than Aetna and BUCA but higher than Cigna and UnitedHealth Group. This positions Medicare below most commercial payers, but above some individual commercial plans.
Rate dispersion, measured by the difference between the 75th and 25th percentiles, varies across payers. Blue Cross Blue Shield shows the widest spread ($96.27 - $41.00 = $55.27), indicating significant variability in rates. UnitedHealth Group has the tightest range ($67.33 - $38.00 = $29.33), suggesting more consistent reimbursement levels. Aetna, Cigna, BUCA, and Medicare fall between these extremes.
The table and chart below present a detailed breakdown of national benchmarks for each payer, including mean rates and percentile values.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.